Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
Explore More Articles
Laser scleral microporation aids near vision without compromising distance vision
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, Robert Ang, MD, discusses results of laser scleral microporation in patients with presbyopia.
read moreRobert Ang Discusses LSM by Ace Vision
Robert T. Ang, refractive surgeon at the Asian Eye Institute in the Philippines, talks to The Ophthalmologist about the ways Laser Scleral Microporation (LSM) therapy offered by Ace Vision Group comes to benefit him and his patients. He discusses the therapy’s mechanism of action, what the procedure involves, and the unique value offered by LSM. …
read moreA New Paradigm Shift: Parts 1 and 2 (Pages 25-31)
DUE TO THE AGING OF THE population, most of our population will spend roughly half of their lives as presby-opes. The etiology of presby-opia has been poorly understood, and treatment options have failed to address the true issues with the disease, creating compro mises in vision that patients are eager to find a solution for, …
read more